Core Insights - Altimmune, Inc. has appointed Linda M. Richardson as Chief Commercial Officer, effective September 16, 2025, bringing over 30 years of experience in sales, marketing, and business development across various therapeutic areas [1][2] - The appointment is seen as a strategic move as the company approaches the initiation of Phase 3 development of pemvidutide for Metabolic Dysfunction-Associated Steatohepatitis (MASH) [2] - Richardson believes pemvidutide has significant potential to improve patient outcomes in hepato-metabolic diseases and sees opportunities in Alcohol Use Disorder and Alcohol-associated Liver Disease [2] Company Overview - Altimmune is a late clinical-stage biopharmaceutical company focused on developing peptide-based therapeutics for liver and cardiometabolic diseases [5] - The lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist targeting MASH, Alcohol Use Disorder, Alcohol-associated Liver Disease, and obesity [5] Inducement Grant Details - As part of her appointment, Richardson will receive options to purchase 278,000 shares and 96,000 restricted stock units (RSUs) [3][4] - The options will vest over four years, with one-fourth vesting on the one-year anniversary of the grant date [3][4]